All 38 people in phase 1 myeloma trial reportedly responded to investigational CAR-T therapy
Medical Xpress reports that more than half of the participants with hard-to-treat myeloma remained progression-free two years later.
TLDR
Medical Xpress reports that all 38 people with hard-to-treat myeloma responded to an investigational CAR-T therapy in a phase 1 trial. More than half remained progression-free two years later, the outlet says.
All 38 people in phase 1 myeloma trial reportedly responded to investigational CAR-T therapy
Medical Xpress reports that more than half of the participants with hard-to-treat myeloma remained progression-free two years later.